Draft:ImpriMed
| Submission declined on 26 December 2024 by Qcne (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 17 December 2024 by Ibjaja055 (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies. Declined by Ibjaja055 14 days ago. | |
ImpriMed
[edit]Company type: Private
Founded: 2017
Headquarters: Silicon Valley
Areas served: Worldwide
Key people: Sungwon Lim, Jamin Koo
Number of employees: 50
Website: https://www.imprimedicine.com
ImpriMed is a biotechnology and precision medicine company leveraging artificial intelligence to improve cancer treatment in cats, dogs and humans. ImpriMed was founded in 2017 by Sungwon Lim and Jamin Koo when they were students at Stanford University. ImpriMed is headquarted in Silicon Valley.
Primarily focused on veterinary oncology, ImpriMed uses diagnostic technologies, such as artificial intelligence and drug sensitivity testing, to tailor cancer treatments for pets, particularly dogs and cats battling lymphoma or leukemia.
ImpriMed’s technology is used by veterinary oncologists to deliver personalized treatments.[1] to canine and feline lymphoma and leukemia patients.
In August 2024, ImpriMed published research[2] on a novel cell-sizing method for feline lymphomas.
In September 2024, ImpriMed announced its expansion into human oncology[3]
References
[edit]- ^ Park, Kate (2023-12-19). "Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology". TechCrunch. Retrieved 2024-12-26.
- ^ Kapoor, Sheena; Sen, Sushmita; Tsang, Josephine; Yap, Qi-Jing; Park, Stanley; Cromarty, Jerry; Swartzfager, Deanna; Choy, Kevin; Lim, Sungwon; Koo, Jamin; Holcomb, Ilona (August 2024). "Prognostic Utility of the Flow Cytometry and Clonality Analysis Results for Feline Lymphomas". Veterinary Sciences. 11 (8): 331. doi:10.3390/vetsci11080331. ISSN 2306-7381. PMID 39195785.
- ^ "ImpriMed unveils cancer treatment forecast technology". MobiHealthNews. 2024-09-23. Retrieved 2024-12-26.
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.